research compound comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
In the conflict's early months it appeared that Gaddafi's government—with its greater fire-power—would be victorious. Both sides disregarded the laws of war, committing human rights abuses, including arbitrary arrests, torture, extrajudicial executions, and revenge attacks. On 26 February, the United Nations Security Council passed Resolution 1970, suspending Libya from the UN Human Rights Council, implementing sanctions and calling for an International Criminal Court (ICC) investigation into the killing of unarmed civilians. In March, the Security Council declared a no-fly zone to protect the civilian population from aerial bombardment, calling on foreign nations to enforce it; it also specifically prohibited foreign occupation. Ignoring this, Qatar sent hundreds of troops to support the dissidents and, along with France and the United Arab Emirates, provided weaponry and military training to the NTC. NATO announced that it would enforce the no-fly zone. On 30 April a NATO airstrike killed Gaddafi's sixth son and three of his grandsons in Tripoli. This Western military intervention was criticized by various leftist governments, including those that had criticized Gaddafi's response to the protests, because they regarded it as an imperialist attempt to secure control of Libya's resources. In June, the ICC issued arrest warrants for Gaddafi, his son Saif al-Islam, and his brother-in-law Abdullah Senussi, head of state security, for charges concerning crimes against humanity.
=== Hi–Hu === Evelyn Hickmans] (1883–1972). British biochemist, pioneer in treatment of phenylketonuria Archibald Vivian Hill FRS (1886–1977). British protein biophysicist at University College London known primarily for work in muscle biochemistry, but also for the Hill equation, still widely used for quantifying protein cooperativity. Nobel Prize in Physiology or Medicine (1922). Robin Hill FRS (1899–1991). British plant biochemist at the University of Cambridge who demonstrated the Hill reaction of photosynthesis. Frank Hird (1920–2014). Australian agricultural biochemist at the University of Melbourne. Dorothy Hodgkin FRS (1910–1994). British X-ray crystallographer at the University of Oxford, pioneer in protein crystallography. Nobel Prize in Chemistry (1964) Jan-Hendrik S. Hofmeyr (b. 1953). South African biochemist at the University of Stellenbosch active in metabolic control analysis. Kenneth Charles Holmes FRS (1934–2021), British molecular biologist and a pioneer in using synchrotron X-ray radiation Mei Hong (born 1970). Chinese-American biophysical chemist known for development solid-state nuclear magnetic resonance to elucidate the structures and mechanisms of membrane proteins Nick Hoogenraad (active from 1969). Australian biochemist, discoverer of the mechanism of the mitochondrial unfolded protein response, Professor of Biochemistry at La Trobe University (1993–2014). Frederick Gowland Hopkins FRS (President) (1861–1947). British biochemist at Cambridge University who discovered tryptophan and worked on vitamins.
Sydney Harbour A unit of volume used in Australia for water. One Sydney Harbour is the amount of water in Sydney Harbour: approximately 562 gigalitres (562,000,000 cubic metres, or 0.562 cubic kilometres); or in terms of the more unusual measures above, about 357 Melbourne Cricket Grounds, 238,000 Olympic Swimming pools, or 476,000 acre-feet. The Grand Canyon With a volume measure approximately 4 orders of magnitude greater than Sydney Harbour, the volume of the Grand Canyon may be used to visualize even larger things, like the magma chamber underneath Yellowstone and other things. According to the National Park Service, the volume of the Grand Canyon is 4.17 trillion cubic metres (5.45 trillion cubic yards) which is 4,170 km3 (1,000 mi3).
Sources: en.wikipedia.org
== Overdose == In the event of arsenic poisoning (manifesting as seizures, muscle weakness, confusion), the administration of the drug should be immediately discontinued, and appropriate treatment should be initiated. Penicillamine is commonly used at a dose of up to 1 g/day. For patients unable to take oral medications, dimercaprol can be administered intramuscularly at a dose of 3 mg/kg body weight every 4 hours until life-threatening symptoms subside. In cases of coagulopathy, DMSA is recommended at a dose of 10 mg/kg body weight every 8 hours for 5 days, followed by every 12 hours for 2 weeks. Kidney dialysis may also be considered.
All corneal grafts are screened for the presence of viruses such as HIV or hepatitis through antibody or nucleic acid testing, and there has never been a reported case of HIV transmission through corneal transplant surgery. Prior to the development of reliable HIV testing, many countries instituted bans on corneal donation by gay men. For example, on 20 May 1994, the United States banned corneal donation by any man who has had sex with another man in the preceding 5 years, even if all HIV testing is negative (a policy which continues to be enforced today).
== Characteristics == Other than nuclear properties, no properties of oganesson or its compounds have been measured; this is due to its extremely limited and expensive production and the fact that it decays very quickly. Thus only predictions are available.
Once gonadotropes are fully developed and functional, these cells compose approximately 15-20% of the anterior pituitary, and gonadotropic cells are larger than other cells of the anterior lobe. Gonadotropes are usually near capillaries and in close proximity to lactotrophs, which suggests a possible paracrine interaction between the two pituitary endocrine cells. In electron micrographs of gonadotropic cells, the rough endoplasmic reticulum is prominent and forms dilated stacks, and the Golgi apparatus are also clearly visible. Cytoplasmic granules within gonadotropic cells are responsible for producing FSH and LH. In most gonadotrophs, the cytoplasm contains both FSH and LH, but there are some gonadotrophs that contain only one of the two hormones. Therefore, there are two different granule populations in gonadotropes, one type being 150-250 nm in diameter and the other being 350-450 nm in diameter. Gonadotropes are usually described as globular and basophilic due to the cells' ability to absorb dyes that appear blue or purple under the microscope due to the cytoplasmic granules that have a high affinity for basic stains.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.